Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.78T
24h Vol:
$12.20B
Dominance:
MSFT:4.81%
Stocklytics Platform
Asset logo  RARE
Ultragenyx Pharmaceutical
RARE
56 / 100
$39.90arrow_drop_down2.87%-$1.18

Performance History

Stocklytics logo
Key Stats
Open$41.29
Prev. Close$41.08
EPS-7.95
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.45B
PE Ratio-
LOWHIGH
Day Range39.42
41.51
52 Week Range31.52
54.98
Ratios
P/B Ratio14.05
Revenue$434.24M
Operating M. %-151.93%
Earnings$0.00
Earnings Growth %14.25%
EBITDA Margin %-126.85%
ROE %-340.05%
EPS-7.95

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$808.45
24H (%)arrow_drop_up0.69%
24H ($)$5.54
MARKET CAP$744.33B
PRICE$516.83
24H (%)arrow_drop_down0.86%
24H ($)-$4.51
MARKET CAP$476.05B
PRICE$149.70
24H (%)arrow_drop_down2.47%
24H ($)-$3.80
MARKET CAP$364.05B
PRICE$131.09
24H (%)0.00%
24H ($)-$0.01
MARKET CAP$332.27B

About Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Headquarters
Novato
Employees
1311
Exchange
NASDAQ
add Ultragenyx Pharmaceutical  to watchlist

Keep an eye on Ultragenyx Pharmaceutical

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Ultragenyx Pharmaceutical 's (RARE) price per share?

The current price per share for Ultragenyx Pharmaceutical (RARE) is $39.9. The stock has seen a price change of -$1.18 recently, indicating a -2.87% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Ultragenyx Pharmaceutical (RARE)?

For Ultragenyx Pharmaceutical (RARE), the 52-week high is $54.98, which is 37.79% from the current price. The 52-week low is $31.52, the current price is 26.59% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Ultragenyx Pharmaceutical (RARE) a growth stock?

Ultragenyx Pharmaceutical (RARE) has shown an average price growth of 0.41% over the past three years. It has received a score of 23 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Ultragenyx Pharmaceutical as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Ultragenyx Pharmaceutical (RARE) stock price performance year to date (YTD)?

As of the latest data, Ultragenyx Pharmaceutical (RARE) has a year-to-date price change of -17.17%. Over the past month, the stock has experienced a price change of -9.01%. Over the last three months, the change has been -20.6%. Over the past six months, the figure is 3.34%. Looking at a longer horizon, the five-year price change stands at -30.27%.

help
Is Ultragenyx Pharmaceutical (RARE) a profitable company?

Ultragenyx Pharmaceutical (RARE) has a net income of -$606.64M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 89.59% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -151.93% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $434.25M, with a revenue growth rate of 19.52%, providing insight into the company's sales performance and growth. The gross profit is $389.04M. Operating income is noted at -$569.21M. Furthermore, the EBITDA is -$550.84M.

help
What is the market capitalization of Ultragenyx Pharmaceutical (RARE)?

Ultragenyx Pharmaceutical (RARE) has a market capitalization of $3.45B. The average daily trading volume is 664.4K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level